ArticleBMC infectious diseases2025
Genomic and clinical characterization of linezolid resistance in Enterococcus species from cancer patients in China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundImmunocompromised cancer patients represent a susceptible population for enterococcal infections. While linezolid remains the primary therapeutic option for vancomycin-resistant Enterococcus (VRE) infections, the emergence of linezolid-resistant Enterococcus (LRE) worldwide has not only exacerbated public health risks but also posed significant challenges to clinical treatment. This study aimed to analyze the prevalence of LRE isolates among cancer patients in China and to investigate the mechanisms of linezolid resistance.
methodsA total of 656 non-repetitive Enterococcus isolates were collected. The susceptibility of Enterococcus to linezolid was determined using the broth microdilution method, and the mechanisms of linezolid resistance were explored through whole-genome sequencing.
resultsAmong 656 isolates, 22 (3.35%) of Enterococcus were found to be resistant to linezolid. The isolates were susceptible to tigecycline, teicoplanin and vancomycin, except for one isolate with vancomycin resistance. The optrA gene was the primary mechanism of acquired linezolid resistance. Eleven LRE isolates had mutations in rplD gene. None of Enterococcus isolates contained cfr or poxtA genes or had mutations in the 23 S rRNA or rplC genes. ST16 (8, 36.36%) was the most prevalent sequence type (ST) in LRE isolates. The optrA gene was predominantly located on the chromosome (15, 68.18%), and was often associated with the fexA gene. The RDK variant (8, 36.36%) was predominant variant of the OptrA protein.
conclusionThe prevalence of LRE in this centre was low (3.35%). The presence of optrA gene was the primary mechanism of acquired linezolid resistance, with ST16 being the most prevalent sequence type. These findings highlight the need for both continued surveillance of LRE and further investigation into the role of OptrA variants in linezolid resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.